Case 2:15-cv Document 1 Filed 04/29/15 Page 1 of 46 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

Size: px
Start display at page:

Download "Case 2:15-cv-01409 Document 1 Filed 04/29/15 Page 1 of 46 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA"

Transcription

1 Case 2:15-cv Document 1 Filed 04/29/15 Page 1 of 46 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA IN RE: XARELTO (RIVAROXABAN) ) MDL No PRODUCTS LIABILITY LITIGATION ) ) SECTION: L ) JUDGE FALLON ) MAG. JUDGE NORTH FRANK PECK, Individually, and on ) Behalf of the Estate of ANN PECK, ) ) ) COMPLAINT AND JURY DEMAND Plaintiff, ) ) Civil Action No.: 2:15-cv-1409 vs. ) ) JANSSEN RESEARCH & ) DEVELOPMENT, LLC f/k/a JOHNSON ) AND JOHNSON PHARMACEUTICALS ) RESEARCH AND DEVELOPMENT LLC; ) JOHNSON & JOHNSON COMPANY; ) JANSSEN ORTHO, LLC; JANSSEN ) PHARMACEUTICALS, INC., f/k/a ) ORTHO- MCNEIL-JANSSEN ) PHARMACEUTICALS, INC.; BAYER ) CORPORATION; BAYER AG; BAYER ) HEALTHCARE LLC; and BAYER ) HEALTHCARE PHARMACEUTICALS ) INC.; and JOHN DOES 1-100, ) ) Defendants. ) ) COMPLAINT & JURY DEMAND COMES NOW the Plaintiff, by and through the undersigned counsel, and hereby submits this Complaint against Defendants Janssen Research & Development, LLC f/k/a Johnson and Johnson PHARMACEUTICALS Research And Development LLC; Johnson & Johnson Company; Janssen Ortho, LLC; Janssen PHARMACEUTICALS, Inc. f/k/a Janssen PHARMACEUTICALS Inc., f/k/a Ortho-McNeil- Janssen PHARMACEUTICALS, Inc.; Bayer Corporation; Bayer AG; Bayer Healthcare, LLC; And Bayer 1

2 Case 2:15-cv Document 1 Filed 04/29/15 Page 2 of 46 Healthcare PHARMACEUTICALS, Inc.; and John Does 1-100, (hereinafter collectively Defendants ) for equitable relief, monetary restitution, and compensatory and punitive damages, arising from the injuries of Decedent as a result of her exposure to the PHARMACEUTICALS product Xarelto and hereby allege: PARTY PLAINTIFFS 1. Decedent ANN PECK (hereinafter, Decedent ), at all times relevant hereto, was a resident and citizen of the United States of America, and was a resident of the State of Idaho. 2. Decedent was born on November 11, Decedent first began using Xare1to on or about March 28, 2013, and used Xarelto as prescribed to her by her physicians up through approximately April 27, As a result of using Defendants' Xarelto, Decedent suffered from internal bleeding and a hemorrhagic stroke, and was caused to sustain severe and permanent personal injuries, pain, suffering, emotional distress, which eventually led to her death on May 4, The injuries and damages sustained by Decedent were caused by her ingestion of Defendants' Xarelto. 6. Plaintiff FRANK PECK, at all times relevant hereto, was, and currently is, a resident and citizen of the State of Idaho. Plaintiff FRANK PECK is the surviving spouse of Decedent and has standing to bring this action (hereinafter, Successor Plaintiff and/or Plaintiff ). Plaintiff has standing to prosecute this action pursuant to Idaho Code Ann (West). PARTY DEFENDANTS 7. Upon information and belief, Defendant JANSSEN RESEARCH & DEVELOPMENT LLC f/k/a JOHNSON AND JOHNSON RESEARCH AND DEVELOPMENT LLC (hereinafter referred to as "JANSSEN R&D") is a limited liability company organized under the laws of New 2

3 Case 2:15-cv Document 1 Filed 04/29/15 Page 3 of 46 Jersey, with a principal place of business at One Johnson & Johnson Plaza, New Brunswick, Middlesex County, New Jersey Defendant JANSSEN R&D is the holder of the approved New Drug Application ("NDA'') for Xarelto as well as the supplemental NDA. 8. As part of its business, JANSSEN R&D is involved in the research, development, sales, and marketing of pharmaceutical products including Xarelto and rivaroxaban. 9. Upon information and belief, Defendant JANSSEN R&D has transacted and conducted business in the State of Oklahoma. 10. Upon information and belief, Defendant JANSSEN R&D has derived substantial revenue from good and products used in the State of Oklahoma. 11. Upon information and belief, Defendant, JANSSEN R&D, expected or should have expected its acts to have consequence within the United States of America and the State of New York and the State of Oklahoma, and derived substantial revenue from interstate commerce within the United States and the State of Oklahoma, more particularly. 12. Upon information and belief, and at all relevant times, Defendant, JANSSEN R&D, was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute the drug Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 13. Upon information and belief, Defendant JANSSEN PHARMACEUTICALS, INC. f/'k/a JANSSEN PHARMACEUTICA INC. 'k/a ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (hereinafter referred to as "JANSSEN PHARM") is a Pennsylvania corporation, having a principal place of business at 1125 Trenton-Harbourton Road, Titusville, New 3

4 Case 2:15-cv Document 1 Filed 04/29/15 Page 4 of 46 Jersey As part of its business, JANSSEN PHARM is involved in the research, development, sales, and marketing of pharmaceutical products including Xarelto and rivaroxaban. 15. Upon information and belief, Defendant, JANSSEN PHARM has transacted and conducted business in the State of Oklahoma. 16. Upon information and belief, Defendant, JANSSEN PHARM, has derived substantial revenue from goods and products used in the State of Oklahoma. 17. Upon information and belief, Defendant, JANSSEN PHARM, expected or should have expected its acts to have consequence within the United States of America and the State of New York and the State of Oklahoma, and derived substantial revenue from interstate commerce within the United States and the State of Oklahoma, more particularly. 18. Upon information and belief, and at all relevant times, Defendant, JANSSEN PHARM, was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute the drug Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 19. Upon information and belief, Defendant JANSSEN ORTHO LLC (hereinafter referred to as "JANSSEN ORTHO") is a limited liability company organized under the laws of Delaware, having a principal place of business at Stateroad 933 Km 0 1, Street Statero, Gurabo, Puerto Rico Defendant JANSSEN ORTHO is a subsidiary of Johnson & Johnson. 20. As part of its business, JANSSEN ORTHO is involved in the research, development, sales, and marketing of pharmaceutical products including Xarelto and rivaroxaban. 4

5 Case 2:15-cv Document 1 Filed 04/29/15 Page 5 of Upon information and belief, Defendant, JANSSEN ORTHO has transacted and conducted business in the State of Oklahoma. 22. Upon information and belief, Defendant, JANSSEN ORTHO, has derived substantial revenue from goods and products used in the State of Oklahoma. 23. Upon information and belief, Defendant, JANSSEN ORTHO, expected or should have expected its acts to have consequence within the United States of America and the State of New York and the State of Oklahoma, and derived substantial revenue from interstate commerce within the United States and the State of Oklahoma, more particularly. 24. Upon information and belief, and at all relevant times, Defendant, JANSSEN ORTHO, was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute the drug Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 25. Upon information and belief, Defendant BAYER HEALTHCARE PHARMACEUTICALS, INC. is, and at all relevant times was, a corporation organized under the laws of the State of Delaware, with its principal place of business in the State of New Jersey. 26. Defendant BAYER HEALTHCARE PHARMACEUTICALS, INC. was formerly known as Berlex Laboratories, Inc., which was formerly known as Berlex, Inc. and BAYER HEALTHCARE PHARMACEUTICALS, INC. is the same corporate entity as Berlex, Inc. and Berlex Laboratories, Inc. 27. As part of its business, BAYER HEALTHCARE PHARMACEUTICALS, INC. is involved in the research, development, sales, and marketing of pharmaceutical products including 5

6 Case 2:15-cv Document 1 Filed 04/29/15 Page 6 of 46 Xarelto and rivaroxaban. 28. Upon information and belief, Defendant, BAYER HEALTHCARE PHARMACEUTICALS, INC., has transacted and conducted business in the State of Oklahoma. 29. Upon information and belief, Defendant, BAYER HEALTHCARE PHARMACEUTICALS, INC., has derived substantial revenue from goods and products used in the and the State of Oklahoma. 30. Upon information and belief Defendant, BAYER HEALTHCARE PHARMACEUTICALS, INC., expected or should have expected its acts to have consequence within the United States of America and the State of Oklahoma, and derived substantial revenue from interstate commerce within the United States and the State of Oklahoma, more particularly. 31. Upon information and belief, and at all relevant times, Defendant, BAYER HEALTHCARE PHARMACEUTICALS, INC., was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute the drug Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 32. Upon information and belief, Defendant BAYER PHARMA AG is a pharmaceutical company domiciled in Germany. 33. Defendant BAYER PHARMA AG is formerly known as Bayer Schering Phanna AG and is the same corporate entity as Bayer Schering Pharma AG. Bayer Schering Pharma AG is formerly known as Schering AG and is the same corporate entity as Schering AG. 34. Upon information and belief, Schering AG was renamed Bayer Schering Pharma AG 6

7 Case 2:15-cv Document 1 Filed 04/29/15 Page 7 of 46 effective December 29, Upon information and belief, Bayer Schering Pharma AG was renamed BAYER PHARMA AG effective July 1, As part of its business, BAYER PHARMA AG is involved in the research, development, sales, and marketing of pharmaceutical products including Xarelto and rivaroxaban. 37. Upon information and belief, Defendant, BAYER PHARMA AG, has derived substantial revenue from goods and products used in the State of New York and the State of Oklahoma. 38. Upon information and belief, Defendant, BAYER PHARMA AG, expected or should have expected its acts to have consequence within the United States of America and the State of New York and the State of Oklahoma, and derived substantial revenue from interstate commerce within the United States and the State of Oklahoma, more particularly. 39. Upon information and belief, and at all relevant times, Defendant, BAYER PHARMA AG, was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute the drug Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 40. Upon information and belief, Defendant BAYER CORPORATION is an Indiana corporation with its principal place of business at 100 Bayer Road, Pittsburgh, Pennsylvania Upon information and belief, Defendant BAYER CORPORATION is the sole member of BAYER HEALTHCARE LLC, which owns 100% of Schering Berlin, Inc., which owns 100% of Defendant BAYER HEALTHCARE PHARMACEUTICALS, INC. As such, Defendant 7

8 Case 2:15-cv Document 1 Filed 04/29/15 Page 8 of 46 BAYER CORPORATION is a parent of Defendant BAYER HEALTHCARE PHARMACEUTICALS, INC. 42. At relevant times, Defendant BAYER CORPORATION was engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, selling, marketing, and/or introducing into interstate commerce, either directly or indirectly through third parties or related entities, its products, including the prescription drug Xarelto. 43. At relevant times, Defendant BAYER CORPORATION conducted regular and sustained business in the State of New York and in the State of Oklahoma, by selling and distributing its products in the State of New York and in the State of Oklahoma and engaged in substantial commerce and business activity in the State of New York and in the State of Oklahoma. 44. Upon information and belief, Defendant BAYER HEALTHCARE LLC is a limited liability company duly formed and existing under and by the virtue of the laws of the State of Delaware, with its principal place of business located in the State of New York. 45. Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE LLC has transacted and conducted business in the State of Oklahoma, and derived substantial revenue from interstate commerce. Defendant BAYER CORPORATION is the sole member of Defendant BAYER HEALTHCARE LLC and as such for purposes of establishing diversity of citizenship, Defendant BAYER HEALTHCARE LLC is a citizen of Indiana and Pennsylvania. 46. Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE LLC expected or should have expected that its acts would have consequences within the United States of America, in the State of Oklahoma, and derived substantial revenue from interstate commerce. 8

9 Case 2:15-cv Document 1 Filed 04/29/15 Page 9 of Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE LLC was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. 48. Upon information and belief, Defendant BAYER HEALTHCARE AG is a company domiciled in Germany and is the parent/holding company of Defendants BAYER CORPORATION, BAYER HEALTHCARE LLC, BAYER HEALTHCARE PHARMACEUTICALS, INC, and BAYER PHARMAAG. 49. Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE AG has transacted and conducted business in the State of Oklahoma, and derived substantial revenue from interstate commerce. 50. Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE AG expected or should have expected that its acts would have consequences within the United States of America, and in the State of Oklahoma, and derived substantial revenue from interstate commerce. 51. Upon information and belief, at all relevant times, Defendant BAYER HEALTHCARE AG exercises dominion and control over Defendants BAYER CORPORATION, BAYER HEALTHCARE LLC, BAYER HEALTHCARE PHARMACEUTICALS, INC., and BAYER PHARMA AG. 52. Upon information and belief, Defendant BAYER AG is a German chemical and pharmaceutical company that is headquartered in Leverkusen, North Rhine-Westphalia, Germany. 9

10 Case 2:15-cv Document 1 Filed 04/29/15 Page 10 of Upon information and belief, Defendant BAYER AG is the third largest pharmaceutical company in the world. 54. Upon information and belief, and at all relevant times Defendant BAYER AG is the parent/holding company of all other named Defendants. 55. Upon information and belief, at all relevant times, Defendant BAYER AG has transacted and conducted business in the State of Oklahoma, and derived substantial revenue from interstate commerce. 56. Upon information and belief, at all relevant times, Defendant BAYER AG expected or should have expected that its acts would have consequences within the United States of America, in the State of Oklahoma, and derived substantial revenue from interstate commerce. 57. Upon information and belief, at all relevant times, Defendant BAYER AG was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and distribute Xarelto for use as an oral anticoagulant, the primary purposes of which are to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat DVT and PE, to reduce the risk of recurrence of DVT and/or PE, and for prophylaxis of DVT for patients undergoing hip and knee replacement surgery. JURISDICTION AND VENUE 58. This Court has jurisdiction over this action pursuant to 28 U.S.C. 1332, because the amount in controversy as to the Plaintiff exceeds $75,000.00, exclusive of interest and costs, and because Defendants are incorporated and have their principal places of business in states other than the state in which the named Plaintiff resides. 59. Pursuant to Pre-Trial Order No. 9, this case is filed directly in this Court for coordination and inclusion to MDL No

11 Case 2:15-cv Document 1 Filed 04/29/15 Page 11 of 46 NATURE OF THE CASE 60. Defendants, directly or by and through their agents, apparent agents, servants or employees designed, manufactured, marketed, advertised, distributed, promoted, labeled, tested and sold Xarelto as an anti-coagulant primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis ("DVT"), to treat pulmonary embolisms ("PE"), and/or to reduce the risk of recurrence of DVT and/or PE. 61. Defendants applied for an initial NDA for Xarelto in July of Xarelto was approved by the Food and Drug Administration ("FDA'') on July 1, 2011 to reduce the risk of blood clots, DVT, and PE following knee and hip replacement surgery. On November 4, 2011 Xarelto was approved as an anti-coagulant primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. On November 2, 2012 the FDA expanded the use of Xarelto to the treatment of patients with DVT and PE, as well as long-term treatment to prevent recurrence of the same. 63. According to the Defendants' marketing and informational materials, referenced in the paragraphs below, and widely disseminated to the consuming public, "Xarelto is the first and only once-a-day prescription blood thinner for patients with AFib not caused by a heart valve problem, that is proven to reduce the risk of stroke -- without routine blood monitoring." As the Defendants state on their website, "XARELTO has been proven to lower the chance of having a stroke if you have atrial fibrillation (AFib ), not caused by a heart valve problem. XARELTO is an anticoagulant, or blood-thinning medicine that works by helping to keep blood clots from forming." The Defendants further claim that "it's been prescribed to more than seven million people around the world to help treat or reduce their risk of dangerous clots" and that it "begins working 1 A/WarningLettersan dnoticeofviolationletterstopharmaceuticalcompanies/ucm

12 Case 2:15-cv Document 1 Filed 04/29/15 Page 12 of 46 a few hours after you start taking it, and keeps working for as long as take it." Defendants further declare that "XARELTO is proven to help treat and prevent DVT and PE blood clots" and that Xarelto "reduc[es] the risk of these dangerous clots [from] happening again." Defendants claim that patients with AFib, DVT, or PE taking Xarelto do not need regular blood monitoring and there are no known dietary restrictions. In addition, patients with AFib only need to take Xarelto once a day with an evening meal Defendants claim that patients with AFib are 5 times more likely than a person without Afib to suffer from a stroke and that "disability is more likely to be severe" and "the outcome is almost twice as likely to be fatal" and "the chances of having another major stroke go up." Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex. It is a highly selective direct Factor Xa inhibitor with oral bioavailability and rapid onset of action. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated Factor II). 69. Defendants routinely marketed Xarelto as a "one size fits all" drug. In their fervent marketing of Xarelto, Defendants' misinformed patients and their healthcare providers as to the necessity to routinely monitor any patient requiring a blood thinning agent. In essence, the Defendants have created a new drug, Xarelto, that is not better than warfarin from a safety perspective, and at best, is only perhaps slightly easier to use and administer. The idea of this apparently easier-to-use anticoagulant evidently appealed to physicians, who were subject to extreme marketing and promotion by the and

13 Case 2:15-cv Document 1 Filed 04/29/15 Page 13 of 46 Defendants, but ignores patient safety. 70. The Defendants' marketing materials suggest that Xarelto represented a therapeutic simplification and therapeutic progress because it did not require patients to undergo periodic monitoring with blood tests and because there were no dietary restrictions. 71. Defendants' boxed warning did not address the increased risk for serious and fatal bleeding, despite the fact that the information listed on their website originating from the Rocket AF clinical trial sponsored by Defendants, states that in comparison to warfarin, patients taking Xarelto have more gastrointestinal bleeds and need more transfusions. In spite of this reference regarding bleeds, the information is still wholly inadequate because, this information was not conveyed in the boxed warning on the Xarelto label According to Institute for Safe Medication Practices, QuarterWatch Report, issued on October 3, 2012, the primary reported adverse event related to Xarelto use "was not the well- understood risk of hemorrhage. Instead, the largest identifiable category was serious blood-clot- related injury--most frequently pulmonary embolism--the very events rivaroxaban is intended to prevent." This lack of efficacy for short term users of Xarelto post hip and knee replacement surgery resulted in about 44% of the reported adverse effects from taking Xarelto. 73. FDA clinical reviewers have stated that "rivaroxaban should not be approved unless the manufacturer conducts further studies to support the efficacy and safety of rivaroxaban" and the FDA website notes that "[a]dverse event reports of thrombocytopenia and venous thromboembolic events 7 were identified" in relationship to Xarelto ". However, this information was not portrayed in the warning section on the warning label. The lack of efficacy of the medication for patients taking

14 Case 2:15-cv Document 1 Filed 04/29/15 Page 14 of 46 Xarelto post hip and knee surgery were not disclosed resulting in patients ingesting Xarelto and physicians prescribing Xarelto without sufficient information to make an accurate decision. 74. Defendants fervently marketed Xarelto using print advertisements, online marketing on their website, and video advertisements with no regard to the accuracy and repercussions of their misleading advertising in favor of increasing sales. 75. In the January/February 2013 issue of WebMD magazine, Defendants placed a print advertisement that resulted in the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) sending a letter stating that their print advertisement was "false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim." Furthermore, the advertisement states "And there are no dosage adjustments" in conflict with the product labeling approved by the FDA As a result of Defendants' intense marketing, "[a]bout 130,000 U.S. prescriptions were written for Xarelto in the first three months of 2012" resulting in large profits as Xarelto costs approximately $3,000 a year versus $200 for generic warfarin As a result of Defendant's extreme marketing tactics, within the United Kingdom, Defendants also made 219 million Euros in sales from Xarelto, more than three times as much as during the same period last year Due to the defective nature of Xarelto, persons who were prescribed and ingested Xarelto, for even a brief period of time, including the Decedent herein, were at increased risk for developing life-threatening bleeds. Due to the flawed formulation of Xarelto, which according to 8 A/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM357833, June 6, 2013 FDA Warning Letter Frank Siebelt, Hans Seidenstuecker, and Christoph Steitz. Reports of side-effects from Bayer s Xarelto grow: Spiegel 14

15 Case 2:15-cv Document 1 Filed 04/29/15 Page 15 of 46 Defendants does not require regular blood monitoring or frequent doctor follow-up, raises concerns about the risk of stroke, bleeding, and blood clots if not taken properly or absorbed properly, particularly in patients with poor renal function. In addition, "[p]rominent U.S. [cardiologists and health care professionals] stress that neither new drug [Xarelto] has a known antidote for a bleeding emergency, as warfarin does." Defendants' PHARMACEUTICALS Xarelto led to 968 suspected undesirable sideeffects including 72 cases of death in Germany in just the first eight months of In addition, The Institute for Safe Medication Practices reported that: A clinical trial with 14,000 patients had shown that rivaroxaban was no worse than warfarin. [40] But reviewers noted that warfarin had not been optimally used. If rivaroxaban were really inferior to optimally used warfarin- -but this was not proven, only suspected--its use could lead to increased death and injury. [41] Reviewers also questioned the convenient once-a-day dosing scheme, saying blood level studies had shown peaks and troughs that could be eliminated by twice-a-day dosing.... As with other anticoagulants, the rate of clinically relevant bleeding in clinical studies was high--15% per year of treatment Even more significantly, in the first quarter of 2012, The Institute for Safe Medication Practices "identified 356 reports of serious, disabling, or fatal injury in which rivaroxaban was the 14 primary suspect drug. The report more than doubled from the previous quarter total of 128 cases." However, when the findings were discussed with Defendants, "the company told us that it had reviewed Frank Siebelt, Hans Seidenstuecker, and Christoph Steitz. Reports of side-effects from Bayer s Xarelto grow: Spiegel 13 Institute for Safe Medication Practices, QuarterWatch Report, October 3, Id. 15

16 Case 2:15-cv Document 1 Filed 04/29/15 Page 16 of the same data and saw no signal of a safety issue that needed to be addressed." Defendants placed more value into ensuring that their profits would continue instead of working on minimizing the serious, disabling, or fatal injuries that were occurring due to the drug they were marketing and promoting. 82. Defendants concealed their knowledge that Xarelto can cause life threatening, irreversible bleeds from the Decedent, other consumers, the general public, and the medical community. The Defendants did not adequately warn of the irreversible nature of Xarelto. Specifically, Defendants did not adequately inform consumers and the prescribing medical community about the risks of uncontrollable bleeds associated with Xarelto usage, nor did Defendants warn or otherwise advise on how to intervene and stabilize a patient should a bleed occur. 83. Moreover, Defendants failed to adequately warn about the lack of an antidote to reverse uncontrolled bleeding caused by Xarelto. Defendants merely indicated that there was a risk for bleeding and side-stepped the important issue of reversing the effects of Xarelto should a bleed occur. Other safer alternatives to Xarelto have an antidote that can reverse uncontrolled bleeding. 84. Importantly, Xarelto still does not have a "black box" warning informing patients or prescribing doctors that Xarelto can cause irreversible bleeds. In fact, a label change as recent as March 2014 still fails to contain a "black box" warning regarding irreversible bleeds Aside from the warning labels, Defendants did not issue a Dear Doctor letter that sufficiently outlined the dangers of administering Xarelto to a patient. In the September 2013 letter to healthcare professionals, Defendants do not mention the lack of an antidote in Xarelto should serious and fatal bleeding occur while a patient was taking Xarelto. 86. The current warning is simply inadequate. The Defendants have failed and continue to 15 Id

17 Case 2:15-cv Document 1 Filed 04/29/15 Page 17 of 46 fail in their duties to warn and protect the consuming public, including the Decedent. 87. In addition to damages for the Defendants inadequate warnings, Xarelto also lacks any benefit sufficient to tolerate the extreme risk posed by the ingestion of this drug. 88. Xarelto is unreasonably dangerous and defective as formulated putting consumers, including Decedent, at an unreasonable risk of suffering needless injuries and death. 89. Defendants willfully, wantonly and with malice withheld the knowledge of increased risk of irreversible bleeds in users of Xarelto to prevent any chances of their product's registrations being delayed or rejected by FDA. 90. As the manufacturers and distributors of Xarelto, Defendants knew or should have known that Xarelto use was associated with irreversible bleeds. 91. With the knowledge of the true relationship between use of Xarelto and irreversible bleeds, rather than taking steps to pull the drug off the market, provide strong warnings, or create an antidote, Defendants promoted and continue to promote Xarelto as a safe and effective treatment for AFib. 92. According to the World Preview report, Defendants' "Xarelto... is estimated to be the 19th-best-selling drug in the world by 2018 and Worldwide sales of Xarelto are expected to jump from $596 million in 2012 to $3.7 billion in 2018." While Defendants enjoy great financial success from their expected blockbuster drug, Xarelto, they continue to place American citizens at risk of severe bleeds and death. 94. Consumers, including Decedent, ANN PECK, who have used Xarelto to reduce the risk of stroke due to Afib or to reduce the risk of blood clots, particularly DVT and PE, following knee or hip replacement surgery, have several alternative safer products available to treat the conditions and

18 Case 2:15-cv Document 1 Filed 04/29/15 Page 18 of 46 have not been adequately warned about the significant risks and lack of benefits associated with Xarelto therapy. 95. Defendants, through their affirmative misrepresentations and omissions, actively concealed from Decedent and Decedents physicians the true and significant risks associated with Xarelto use. 96. As a result of Defendants' actions, Decedent and Decedent s physicians were unaware, and could not have reasonably known or have learned through reasonable diligence, that Decedent would be exposed to the risks identified in this Complaint. The increased risks and subsequent medical damages associated with Decedent s Xarelto use were the direct and proximate result of Defendants' conduct. FACTUAL ALLEGATIONS 97. On or around March 28, 2013, Decedent was first prescribed and began taking Xarelto upon direction of her physician. Subsequently, as a direct result of Decedent s ingestion of Xarelto, Decedent suffered a hemorrhagic stroke and internal bleeding. As a result, Decedent died on or about May 4, As a direct result of being prescribed Xarelto for this period of time, Decedent suffered significant injuries and death, such as those described above. 99. As a proximate result of Defendants' acts and omissions, Decedent suffered the injuries and death described hereinabove due to Decedent s ingestion of Xarelto. Plaintiff accordingly seeks damages associated with these injuries and death Decedent would not have used Xarelto had Defendants properly disclosed the risks associated with its use, as safer alternatives without the aforesaid risks were available. 18

19 Case 2:15-cv Document 1 Filed 04/29/15 Page 19 of 46 EQUITABLE TOLLING OF APPLICABLE STATUTES OF LIMITATION 101. Plaintiff incorporates by reference each and every paragraph of this Complaint as if fully set forth herein and further alleges as follows: 102. The running of any statute of limitations has been tolled by reason of Defendants' fraudulent concealment. Defendants, through failing to disclose, for three years, the truth about the safety and efficacy of Xarelto, to Decedent s physicians and/or Decedent, and misrepresenting Xarelto as safe and efficacious for its intended use, actively concealed from said individuals the true risks associated with the use of Xarelto drug products Decedent and Successor Plaintiff had no knowledge that Defendants were engaged in the wrongdoing alleged herein. Because of the fraudulent acts of concealment of wrongdoing by the Defendants, Successor Plaintiff could not have reasonably discovered the wrongdoing at any time prior to the commencement of this action Decedent, nor Decedent s physicians, could have possiblydetermined the nature, extent and identity of related health risks associated with Xarelto. Decedent and Decedent s physicians reasonably relied on Defendants to disseminate truthful and accurate safety and efficacy information about its drug and warn of the side effects complained of herein Furthermore, Defendants are estopped from relying on any statute of limitations because of their fraudulent concealment of the defective nature of Xarelto. Defendants were under a duty to disclose the true character, quality, and nature of Xarelto because this was nonpublic information over which the Defendants have, and continue to have, exclusive control, and because Defendants knew this information was not available to the Decedent or her physicians. In addition, the Defendants are estopped from relying on any statute of limitations because of their concealment of these facts WHEREFORE, Successor Plaintiff demands judgment against Defendants for 19

20 Case 2:15-cv Document 1 Filed 04/29/15 Page 20 of 46 compensatory and punitive damages, together with interest, costs of suit, attorneys fees, and all such other relief as the Court deems proper. COUNT I STRICT PRODUCTS LIABILITY- FAILURE TO WARN Comes now Successor Plaintiff and for Count I of this Complaint alleges: 107. Plaintiff incorporates by reference each and every paragraph of this Complaint as if fully set forth herein and further alleges as follows: 108. Plaintiff, FRANK PECK, individually and as successor in interest of ANN PECK, brings Count I of this complaint for the wrongful death of ANN PECK Defendants owed a duty of reasonable care to adequately warn of the risks associated with the use of Xarelto to Decedent and the general public Defendants knew or reasonably should have known that the warnings provided to users of Xarelto regarding the risks associated with its use were incorrect and misleading in at least the following material respects: a. Xarelto was unaccompanied by proper warnings regarding all possible side effects associated with its use and the comparative severity, incidence, and duration of such adverse effects; and b. Xarelto was defective due to inadequate post-marketing warnings or instructions, because Defendants failed to provide adequate warnings to users or consumers and continued aggressively to promote Xarelto, even after it knew or should have known of the risks of injury from this drug; and c. Xarelto was unaccompanied by proper warnings regarding irreversible bleeding caused by Xarelto and Defendants continued to aggressively promote Xarelto, 20

Case 1:14-cv-06494 Document 1 Filed 11/04/14 Page 1 of 46 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NEW YORK

Case 1:14-cv-06494 Document 1 Filed 11/04/14 Page 1 of 46 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NEW YORK Case 1:14-cv-06494 Document 1 Filed 11/04/14 Page 1 of 46 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NEW YORK SUZANN GOBLE, Individually and on Behalf of the Estate of EMILY PIGG,

More information

Case 2:15-cv-00886 Document 1 Filed 03/20/15 Page 1 of 42 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA

Case 2:15-cv-00886 Document 1 Filed 03/20/15 Page 1 of 42 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA Case 2:15-cv-00886 Document 1 Filed 03/20/15 Page 1 of 42 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA DANNY JULIEN, Individually and as Personal Representative of the Estate of TOMMY

More information

Case 0:14-cv-61448-JAL Document 1 Entered on FLSD Docket 06/23/2014 Page 1 of 43 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA

Case 0:14-cv-61448-JAL Document 1 Entered on FLSD Docket 06/23/2014 Page 1 of 43 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA Case 0:14-cv-61448-JAL Document 1 Entered on FLSD Docket 06/23/2014 Page 1 of 43 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA NANCY PACKARD, Individually and as Personal Representative

More information

Case 8:15-cv-00144-VMC-EAJ Document 8 Filed 01/27/15 Page 1 of 49 PageID 68

Case 8:15-cv-00144-VMC-EAJ Document 8 Filed 01/27/15 Page 1 of 49 PageID 68 Case 8:15-cv-00144-VMC-EAJ Document 8 Filed 01/27/15 Page 1 of 49 PageID 68 IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRECT OF FLORIDA TAMPA DIVISION, individually and as executor ) de son

More information

Case 3:15-cv-02774-MAS-DEA Document 1 Filed 04/20/15 Page 1 of 38 PageID: 1

Case 3:15-cv-02774-MAS-DEA Document 1 Filed 04/20/15 Page 1 of 38 PageID: 1 Case 3:15-cv-02774-MAS-DEA Document 1 Filed 04/20/15 Page 1 of 38 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT NEW JERSEY --------------------------------------------------------------------------------X

More information

CV 1 4 45 24. .7,Nt Jo. -against- Plaintiff,

CV 1 4 45 24. .7,Nt Jo. -against- Plaintiff, Case 1:14-cv-04524-DLI-MDG Document 1 Filed 07/29/14 Page 1 of 47 PagelD 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK JEANNE JEFFCOAT, r l ir X rç CV 1 4 45 24 CASE NUMBER: -against- Plaintiff,.7,Nt

More information

LEvy mj FILED. -against- INC., BAYER HEALTHCARE PHARMACEUTICALS, INC., BAYER PHARMA AG, BAYER CORPORATION, BAYER HEALTHCARE LLC, BAYER HEALTHCARE AG,

LEvy mj FILED. -against- INC., BAYER HEALTHCARE PHARMACEUTICALS, INC., BAYER PHARMA AG, BAYER CORPORATION, BAYER HEALTHCARE LLC, BAYER HEALTHCARE AG, I Case 1:14-cv-05133-FB-RML Document 1 Filed 08/29/14 Page 1 of 47 PagelD 1 UNITED STATES DISTRICT COURT :4: -F V, PAit FILED c EASTERN DISTRICT OF NEW YORK, L2 29 pj X SHIRLEY BOYNTON and tf, S. JAMES

More information

Case 2:14-cv-00159-cr Document 1 Filed 07/25/14 Page 1 of 54

Case 2:14-cv-00159-cr Document 1 Filed 07/25/14 Page 1 of 54 Case 2:14-cv-00159-cr Document 1 Filed 07/25/14 Page 1 of 54 RUTH E. McGOWAN, as the Executrix for and on behalf of the heirs ofthe ESTATE of THOMAS C. DUNKLEY, v. Plaintiff,, U.S. OIS77::::T f; DISTRICT

More information

JOINT COMPLAINT REVISED DRAFT (JANUARY, 2016)

JOINT COMPLAINT REVISED DRAFT (JANUARY, 2016) UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA ANDY APPLE, BRIAN BARNONE, CANDY CORN, DONNA DIXON, ELLEN ELKIN, FRED FINKEL, AND GEAUX GIROD v. Plaintiffs, JANSSEN RESEARCH & DEVELOPMENT LLC

More information

CV 1 4 4 8 4 1 AND DEMAND. OCK j"' FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY SCANLON, M.J.

CV 1 4 4 8 4 1 AND DEMAND. OCK j' FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY SCANLON, M.J. Case 1:14-cv-04841-FB-VMS Document 1 FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY AUG 1 2014 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK BROOKLYN OFFICE.1/4;1,

More information

CV 1 4 4 8 4 1 AND DEMAND. OCK j"' FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY SCANLON, M.J.

CV 1 4 4 8 4 1 AND DEMAND. OCK j' FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY SCANLON, M.J. Case 1:14-cv-04841-FB-VMS Document 1 FiledpitEla Page 1 of 47 PagelD 1 IN CLERK'S OFFICE U 5-DISTRICT COURT EDICY AUG 1 2014 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK BROOKLYN OFFICE.1/4;1,

More information

Case 2:16-cv-02392 Document 1 Filed 03/22/16 Page 1 of 54 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

Case 2:16-cv-02392 Document 1 Filed 03/22/16 Page 1 of 54 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA Case 2:16-cv-02392 Document 1 Filed 03/22/16 Page 1 of 54 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA SANDRA BROWN, ROBERT CAPPS, BERNARD GAUS, JEROME JOHNSON, JUNE PIKE, CLAUDE RAYE, JOHN

More information

XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS

XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS 1 In 2011, a new anticoagulant drug was approved by the U.S. Food and Drug Administration (FDA). The new drug Xarelto was marketed as a more convenient

More information

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION LAUREN L. MURPHY : 1127 Euclid Ave. #810 : Cleveland, OH 44115 : : Plaintiff, : Civil Action No. : v. : : BAYER CORPORATION, : an

More information

Case 3:12-cv-60021-DRH-SCW Document 1 Filed 03/06/12 Page 1 of 44 Page ID #1

Case 3:12-cv-60021-DRH-SCW Document 1 Filed 03/06/12 Page 1 of 44 Page ID #1 Case 3:12-cv-60021-DRH-SCW Document 1 Filed 03/06/12 Page 1 of 44 Page ID #1 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF KENTUCKY LONDON DIVISION HELEN JEAN HAWKINS AND JOHN EDWARD

More information

IN THE U.S. DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

IN THE U.S. DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) IN THE U.S. DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION ANGELA BECK 13125 Kay Street Paulding, Ohio 45879 MARTIN BECK 13125 Kay Street Paulding, Ohio 45879 v. Plaintiffs, BAYER CORPORATION

More information

Case 6:12-cv-02055 Document 1 Filed 07/30/12 Page 1 of 35 PageID #: 1 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF LOUISIANA

Case 6:12-cv-02055 Document 1 Filed 07/30/12 Page 1 of 35 PageID #: 1 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF LOUISIANA Case 6:12-cv-02055 Document 1 Filed 07/30/12 Page 1 of 35 PageID #: 1 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF LOUISIANA IN RE: ACTOS PRODUCT LIABILITY ) MDL No. 6:11-md-2299 LITIGATION ) ) JUDGE

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Licence for use in the UK is expected before the end of 2011

Licence for use in the UK is expected before the end of 2011 News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

Case 3:14-cv-02361-P Document 1 Filed 06/30/14 Page 1 of 9 PageID 1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

Case 3:14-cv-02361-P Document 1 Filed 06/30/14 Page 1 of 9 PageID 1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION Case 3:14-cv-02361-P Document 1 Filed 06/30/14 Page 1 of 9 PageID 1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION JAMES MICHAEL CLINE, Plaintiff VS. Civil Action No. 3:14-cv-2361

More information

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF ILLINOIS PEORIA DIVISION

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF ILLINOIS PEORIA DIVISION UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF ILLINOIS PEORIA DIVISION MARCIA OLSON, ) ) Plaintiff, ) ) Case No: v. ) ) HOWMEDICA OSTEONICS CORP. d/b/a ) STRYKER ORTHOPAEDICS, ) JURY TRIAL DEMANDED

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

2:12-cv-12969-SFC-RSW Doc # 1 Filed 07/06/12 Pg 1 of 8 Pg ID 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

2:12-cv-12969-SFC-RSW Doc # 1 Filed 07/06/12 Pg 1 of 8 Pg ID 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION 2:12-cv-12969-SFC-RSW Doc # 1 Filed 07/06/12 Pg 1 of 8 Pg ID 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION LAWANDA SALISBURY, Plaintiff, v. INTUITIVE SURGICAL, INC. Defendants.

More information

Case 3:08-cv-00920-JAP-JJH Document 1 Filed 02/20/2008 Page 1 of 13 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ) ) ) ) ) ) ) ) ) ) ) ) ) )

Case 3:08-cv-00920-JAP-JJH Document 1 Filed 02/20/2008 Page 1 of 13 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ) ) ) ) ) ) ) ) ) ) ) ) ) ) Case 3:08-cv-00920-JAP-JJH Document 1 Filed 02/20/2008 Page 1 of 13 Laurence M. Rosen, Esq. THE ROSEN LAW FIRM, P.A. 236 Tillou Road South Orange, NJ 07079 Telephone: (973 313-1887 Fax: (973 833-0399 lrosen@rosenlegal.com

More information

SUPERIOR COURT PROVINCE OF QUEBEC DISTRICT OF MONTREAL D. GAGNON. -vs.- and. and. and. and

SUPERIOR COURT PROVINCE OF QUEBEC DISTRICT OF MONTREAL D. GAGNON. -vs.- and. and. and. and 1 CANADA PROVINCE OF QUEBEC DISTRICT OF MONTREAL NO: 500-06-000732-152 (Class Action) SUPERIOR COURT D. GAGNON Petitioner -vs.- JANSSEN INC., legal person duly constituted, having its head office at 19

More information

: : : : : : : : : : : : : : : : : : : : : : : : :

: : : : : : : : : : : : : : : : : : : : : : : : : THE D ONOFRIO FIRM, LLC By: Louis F. D Onofrio, Esquire (ID No. 90901) Email: ldonofrio@donofriofirm.com By: Heather K. D Onofrio, Esquire (ID No. 91170) Email: hdonofrio@donofriofirm.com 303 Chestnut

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

XARELTO: WHAT YOU NEED TO KNOW ABOUT IT

XARELTO: WHAT YOU NEED TO KNOW ABOUT IT XARELTO: WHAT YOU NEED TO KNOW ABOUT IT 1 Surgeries to replace knees and hips are commonplace in today s hospitals. Xarelto is a drug prescribed by doctors to prevent blood clots after those surgeries.

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

GRAY, L.L.C. 760 ROUTE 10 WEST, SUITE 203 WHIPPANY, NEW JERSEY 07981 PH: 973-240-7313 F: 973-240-7316 Attorneys for Plaintiff Henry Kent

GRAY, L.L.C. 760 ROUTE 10 WEST, SUITE 203 WHIPPANY, NEW JERSEY 07981 PH: 973-240-7313 F: 973-240-7316 Attorneys for Plaintiff Henry Kent POMPELIO, FOREMAN & GRAY, L.L.C. 760 ROUTE 10 WEST, SUITE 203 WHIPPANY, NEW JERSEY 07981 PH: 973-240-7313 F: 973-240-7316 Attorneys for Plaintiff Henry Kent HENRY KENT, vs. Plaintiff, SMILES II RESTAURANT,

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Filing # 22009228 Electronically Filed 12/29/2014 03:48:06 PM

Filing # 22009228 Electronically Filed 12/29/2014 03:48:06 PM Filing # 22009228 Electronically Filed 12/29/2014 03:48:06 PM PENELOPE BELVOIR, as Executor de son Tort for the Pending Estate of Robert Belvoir, Deceased, vs. Plaintiff, ROPES COURSES, INC., FB ORLANDO

More information

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

CIVIL ACTION COMPLAINT. Plaintiff, Stella H. Pidgeon, Individually and Administratrix of the Estate of her

CIVIL ACTION COMPLAINT. Plaintiff, Stella H. Pidgeon, Individually and Administratrix of the Estate of her ANAPOL, SCHWARTZ, WEISS, COHAN FELDMAN & SMALLEY, P.C. By: James R. Ronca, Esquire Attorney I.D. No. 25631 1710 Spruce St. Philadelphia, PA 19103 (215) 790-4584 Attorneys for Plaintiff STELLA H. PIDGEON,

More information

Case 2:10-cv-03242-SSV-DEK Document 27 Filed 12/07/10 Page 1 of 17 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

Case 2:10-cv-03242-SSV-DEK Document 27 Filed 12/07/10 Page 1 of 17 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA Case 2:10-cv-03242-SSV-DEK Document 27 Filed 12/07/10 Page 1 of 17 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA KATHLEEN A. BRANDNER, individually, and CLASS ACTION COMPLAINT on behalf of

More information

IN THE CIRCUIT COURT OF GREENE COUNTY, MISSOURI

IN THE CIRCUIT COURT OF GREENE COUNTY, MISSOURI IN THE CIRCUIT COURT OF GREENE COUNTY, MISSOURI JANE DOE INDIVIDUALLY ) and on BEHALF OF ) THE CLASS OF PERSONS ) DESIGNATED BY 537.080, ) ) Plaintiff, ) ) Case Number *************** vs. ) ) DEFENDANT

More information

Products Liability: Putting a Product on the U.S. Market. Natalia R. Medley Crowell & Moring LLP 14 November 2012

Products Liability: Putting a Product on the U.S. Market. Natalia R. Medley Crowell & Moring LLP 14 November 2012 Products Liability: Putting a Product on the U.S. Market Natalia R. Medley Crowell & Moring LLP 14 November 2012 Overview Regulation of Products» Federal agencies» State laws Product Liability Lawsuits»

More information

Attorney for Plaintiff SUPERIOR COURT OF THE STATE OF CALIFORNIA LOS ANGELES COUNTY CENTRAL DISTRICT STANLEY MOSK COURTHOUSE

Attorney for Plaintiff SUPERIOR COURT OF THE STATE OF CALIFORNIA LOS ANGELES COUNTY CENTRAL DISTRICT STANLEY MOSK COURTHOUSE VACHON LAW FIRM Michael R. Vachon, Esq. (SBN ) 0 Via Del Campo, Suite San Diego, California Tel.: () -0 Fax: () - Attorney for Plaintiff SUPERIOR COURT OF THE STATE OF CALIFORNIA LOS ANGELES COUNTY CENTRAL

More information

CAUSE NO. STATE OF TEXAS, IN THE DISTRICT COURT OF Plaintiff LIFESTREAM PURIFICATION SYSTEMS, LLC. DALLAS COUNTY, T E X A S

CAUSE NO. STATE OF TEXAS, IN THE DISTRICT COURT OF Plaintiff LIFESTREAM PURIFICATION SYSTEMS, LLC. DALLAS COUNTY, T E X A S CAUSE NO. STATE OF TEXAS, IN THE DISTRICT COURT OF Plaintiff VS. LIFESTREAM PURIFICATION SYSTEMS, LLC. DALLAS COUNTY, T E X A S Defendant. JUDICIAL DISTRICT FINAL JUDGMENT AND AGREED PERMANENT INJUNCTION

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEVADA

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEVADA Case 2:06-cv-00132-KJD-LRL Document 1 Filed 02/03/2006 Page 1 of 10 Louis V. Traeger California State Bar No. 38714 ltraeger@cftc.gov William P. Janulis IL ARDC No. 1326449 Rosemary Hollinger IL ARDC No.

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

IN THE THIRD JUDICIAL DISTRICT COURT, SALT LAKE COUNTY STATE OF UTAH. Case No. : Judge:

IN THE THIRD JUDICIAL DISTRICT COURT, SALT LAKE COUNTY STATE OF UTAH. Case No. : Judge: Alan W. Mortensen (6616) DEWSNUP, KING & OLSEN 36 South State Street, Ste. 2400 Salt Lake City, UT 84111 Telephone (801) 533-0400 Facsimile (801) 363-4218 Attorneys for Plaintiffs IN THE THIRD JUDICIAL

More information

SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF LOS ANGELES

SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF LOS ANGELES Fernando F. Chavez, Esq. SBN 0 CHAVEZ LAW GROUP 00 West Beverly Blvd., Montebello, Ca 00 Phone: () 00-0, Facsimile: (0) 1-01 E-mail: ffchavez0@gmail.com Attorneys for Plaintiffs SUPERIOR COURT OF THE STATE

More information

Case: 1:16-cv-00951 Document #: 1 Filed: 01/22/16 Page 1 of 18 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

Case: 1:16-cv-00951 Document #: 1 Filed: 01/22/16 Page 1 of 18 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION Case: 1:16-cv-00951 Document #: 1 Filed: 01/22/16 Page 1 of 18 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION PAMELA ANDERSON, Individually and ) as Independent

More information

1416-CV14463. 1. Plaintiff is a resident of Jackson County, Missouri and is the biological mother of

1416-CV14463. 1. Plaintiff is a resident of Jackson County, Missouri and is the biological mother of IN THE CIRCUIT COURT FOR JACKSON COT]NTY, MISSOURI AT INDEPENDENCE TAMMY BRYANT, Natural Mother of Kevin'Wahlers, Deceased, vs. Plaintiff ASRA, LLC dlbla 40 HIGHV/AY SINCLAIR Serve Registered Agent: Rizwan

More information

Case: 1:15-cv-09957 Document #: 1 Filed: 11/04/15 Page 1 of 10 PageID #:1

Case: 1:15-cv-09957 Document #: 1 Filed: 11/04/15 Page 1 of 10 PageID #:1 Case: 1:15-cv-09957 Document #: 1 Filed: 11/04/15 Page 1 of 10 PageID #:1 JACLYN PAZERA Plaintiff, IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION v. Case No.

More information

Complaint as permitted by Case Management Order # 4 and Implementing Order PARTIES, JURISDICTION AND VENUE

Complaint as permitted by Case Management Order # 4 and Implementing Order PARTIES, JURISDICTION AND VENUE [INSERT NAME], Plaintiff(s) vs. HOWMEDICA OSTEONICS CORPORATION, a New Jersey Corporation, d/b/a STRYKER ORTHOPAEDICS, JILL DOE MANUFACTURERS (1-10), JACK DOE WHOLESALERS (1-10), JAKE DOE SELLERS (1-10),

More information

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION. Judge:

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION. Judge: IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO WESTERN DIVISION PATRICK D. REGAN, VALERIE C. REGAN, ELIZABETH VAUGHAN ON BEHALF OF THE BANKRUPTCY ESTATE IN RE PATRICK D. REGAN AND

More information

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF WASHINGTON AT SEATTLE NO. Defendant

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF WASHINGTON AT SEATTLE NO. Defendant William D. Marler Marler Clark LLP PS 01 Second Ave, Suite 00 Seattle, WA 1-0 Ph: IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF WASHINGTON AT SEATTLE DOROTHY H. PEARCE, vs. Plaintiff,

More information

THE STATE OF MINNESOTA TO THE ABOVE-NAMED DEFENDANTS: the Complaint which is herewith served upon you within twenty (20) days after the service of

THE STATE OF MINNESOTA TO THE ABOVE-NAMED DEFENDANTS: the Complaint which is herewith served upon you within twenty (20) days after the service of STATE OF MINNESOTA COUNTY OF DAKOTA DISTRICT COURT FIRST JUDICIAL DISTRICT CASE TYPE: Personal Injury ERIC GUSTAFSON and JENNIFER GUSTAFSON, Individually and as parents and natural guardians for CALLIE

More information

i4n 10/28/03 05:08 PM ET Master Complaint No. 12

i4n 10/28/03 05:08 PM ET Master Complaint No. 12 i4n 10/28/03 05:08 PM ET Master Complaint No. 12 . 10/28/03 c ASBESTOS DOCKET STATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF WAYNE *, Personal Representative of the Estate of *, Deceased, Plaintiff,

More information

IN THE CIRCUIT COURT OF THE NINTH JUDICAL CIRCUIT IN AND FOR ORANGE COUNTY FLORIDA. Case No.

IN THE CIRCUIT COURT OF THE NINTH JUDICAL CIRCUIT IN AND FOR ORANGE COUNTY FLORIDA. Case No. IN THE CIRCUIT COURT OF THE NINTH JUDICAL CIRCUIT IN AND FOR ORANGE COUNTY FLORIDA SUZANNE MATTEIS, Plaintiff, DARDEN CORPORATION, a Florida Corporation. v. Case No. COMPLAINT FOR DAMAGES FOR PERSONAL

More information

BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) )

BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) ) BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION In re: Xarelto (Rivaroxaban Products Liability Litigation Kieonna Littlejohn and Audrey Oakley v. Janssen Research & Development, et

More information

Case 2:14-md-02592-EEF-MBN Document 1785 Filed 12/17/15 Page 1 of 5 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

Case 2:14-md-02592-EEF-MBN Document 1785 Filed 12/17/15 Page 1 of 5 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA Case 2:14-md-02592-EEF-MBN Document 1785 Filed 12/17/15 Page 1 of 5 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA IN RE: XARELTO (RIVAROXABAN) * MDL NO. 2592 PRODUCTS LIABILITY LITIGATION

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA BROWARD DIVISION. Plaintiff, Case No.: COMPLAINT

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA BROWARD DIVISION. Plaintiff, Case No.: COMPLAINT UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA BROWARD DIVISION NANCY PRITCHARD, v. Plaintiff, Case No.: KAPLAN HIGHER EDUCATION CORPORATION; KAPLAN HIGHER EDUCATION CORPORATION, as PLAN ADMINISTRATOR;

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) COMPLAINT THE PARTIES

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) COMPLAINT THE PARTIES IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AEROSCOUT, LTD. and AEROSCOUT, INC., v. CENTRAK INC., Plaintiffs, Defendant. C.A. No. JURY TRIAL DEMANDED COMPLAINT Plaintiffs AeroScout,

More information

Case 3:10-cv-02236-DRD Document 31 Filed 05/05/11 Page 1 of 9

Case 3:10-cv-02236-DRD Document 31 Filed 05/05/11 Page 1 of 9 Case 3:10-cv-02236-DRD Document 31 Filed 05/05/11 Page 1 of 9 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO DAVID ASHE Plaintiff, CIVIL NO. 10-2236 ( DRD ) vs. DISTRIBUIDORA NORMA,

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about

More information

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) IN THE SUPERIOR COURT OF THE STATE OF DELAWARE IN RE ASBESTOS LITIGATION: STEVEN P. SCHULTZ and KIMBERLY S. SCHULTZ, Plaintiffs, v. COLGATE-PALMOLIVE COMPANY; COTY, INC.; CYPRUS AMAX MINERALS COMPANY (sued

More information

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Criminal No.:

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Criminal No.: UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Criminal No.: UNITED STATES OF AMERICA, ) ) Plaintiff, ) DEFERRED PROSECUTION ) AGREEMENT v. ) ) BIXBY ENERGY SYSTEMS, INC., ) ) Defendant. ) The United

More information

IN THE UNITED STATES DISTRICT COURT DISTRICT OF

IN THE UNITED STATES DISTRICT COURT DISTRICT OF IN THE UNITED STATES DISTRICT COURT DISTRICT OF UNITED STATES OF AMERICA ) Civil Action No. Ex rel. ) ) FILED IN CAMERA AND Plaintiff, ) UNDER SEAL ) vs. ) FALSE CLAIMS ACT ) MEDICAID FRAUD, ), and ) JURY

More information

IN THE CIRCUIT COURT OF MOBILE COUNTY, ALABAMA. v. Civil Action No.:CL12-1617 Plaintiff Demands Trial by Jury COMPLAINT

IN THE CIRCUIT COURT OF MOBILE COUNTY, ALABAMA. v. Civil Action No.:CL12-1617 Plaintiff Demands Trial by Jury COMPLAINT IN THE CIRCUIT COURT OF MOBILE COUNTY, ALABAMA MIGUEL RUIZ, HUSAIN SALAH, MOHAMED ABDELWAHAM, ANDREW BRZEZINSKI, MARIO CLOTTER, HECTOR SANCHEZ, CLIFFORD LACON, and JIMMY SABGA, RICHARD HICKS Plaintiff,

More information

SUPERIOR COURT OF THE STATE OF CALIFORNIA IN AND FOR THE COUNTY OF SOMEWHERE ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

SUPERIOR COURT OF THE STATE OF CALIFORNIA IN AND FOR THE COUNTY OF SOMEWHERE ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Harvey C. Berger (SBN POPE & BERGER 0 West "C" Street, Suite 100 San Diego, California 1 Telephone: (1-1 Facsimile: (1 - Attorneys for Plaintiff PLAINTIFF SUPERIOR COURT OF THE STATE OF CALIFORNIA IN AND

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Case 1:13-cv-00001-SEB-TAB Document 1 Filed 01/02/13 Page 1 of 7 PageID #: 1

Case 1:13-cv-00001-SEB-TAB Document 1 Filed 01/02/13 Page 1 of 7 PageID #: 1 Case 1:13-cv-00001-SEB-TAB Document 1 Filed 01/02/13 Page 1 of 7 PageID #: 1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION JAIME MILLER, Plaintiff v. No.: 1:13-cv-1 CITY

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Case 2:12-cv-07090-SRC-CLW Document 1 Filed 11/14/12 Page 1 of 5 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

Case 2:12-cv-07090-SRC-CLW Document 1 Filed 11/14/12 Page 1 of 5 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY Case 212-cv-07090-SRC-CLW Document 1 Filed 11/14/12 Page 1 of 5 PageID 1 Attorney(s) for Plaintiff Norman Kornitzer IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY NORMAN KORNITZER,

More information

Ctu :00.bvr@02B2SNBDoDsoenteffi 1 FiRib00l&em8 P&ryd 6fd 9

Ctu :00.bvr@02B2SNBDoDsoenteffi 1 FiRib00l&em8 P&ryd 6fd 9 Ctu :00.bvr@02B2SNBDoDsoenteffi 1 FiRib00l&em8 P&ryd 6fd 9 IN THE TINITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA MICHAEL DOMBROSKI, a minor, and MATTHEW DOMBROSKI' a minor, by and

More information

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION Case: 1:15-cv-06605 Document #: 1 Filed: 07/28/15 Page 1 of 17 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION ) LINDA J. ROSSBACH, Individually and ) Case No. On

More information

IN THE THIRD JUDICIAL DISTRICT COURT, SALT LAKE COUNTY, UTAH

IN THE THIRD JUDICIAL DISTRICT COURT, SALT LAKE COUNTY, UTAH Robert G. Gilchrist (3715) Jeff M. Sbaih (14014) EISENBERG GILCHRIST & CUTT 900 Parkside Tower 215 South State Street Salt Lake City, Utah 84111 Phone: (801) 366-9100 Email: rgichrist@egclegal.com Email:

More information

December 10, 2015. Dear Dr. Ostroff:

December 10, 2015. Dear Dr. Ostroff: December 10, 2015 Stephen Ostroff, M.D. Acting Commissioner Food and Drug Administration Department of Health and Human Services WO 2200 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Dear Dr.

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

IN THE CIRCUIT COURT OF THE FIFTEENTH JUDICIAL CIRCUIT IN AND FOR PALM BEACH COUNTY, FLORIDA CIVIL DIVISION COMPLAINT

IN THE CIRCUIT COURT OF THE FIFTEENTH JUDICIAL CIRCUIT IN AND FOR PALM BEACH COUNTY, FLORIDA CIVIL DIVISION COMPLAINT IN THE CIRCUIT COURT OF THE FIFTEENTH JUDICIAL CIRCUIT IN AND FOR PALM BEACH COUNTY, FLORIDA CIVIL DIVISION Plaintiff, CASE NUMBER: JUDGE: vs. Defendant. / COMPLAINT COMES NOW, Plaintiff,, and hereby sues

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF NORTH CAROLINA

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF NORTH CAROLINA Case 1:15-cv-00224-TDS-LPA Document 1 Filed 03/12/15 Page 1 of 15 UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF NORTH CAROLINA JAMES J. MAZUR, DPM, and ) JAMES MAZUR, D.P.M., P.A., on behalf of ) themselves

More information

NC General Statutes - Chapter 99B 1

NC General Statutes - Chapter 99B 1 Chapter 99B. Products Liability. 99B-1. Definitions. When used in this Chapter, unless the context otherwise requires: (1) "Claimant" means a person or other entity asserting a claim and, if said claim

More information

2:14-cv-03460-RMG Date Filed 08/27/14 Entry Number 1 Page 1 of 8

2:14-cv-03460-RMG Date Filed 08/27/14 Entry Number 1 Page 1 of 8 2:14-cv-03460-RMG Date Filed 08/27/14 Entry Number 1 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION DANIEL CHRISTOPHER DRUMMOND AND PAULANN PERRY,

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Civil Action No. INFANT SWIMMING RESEARCH, INC., v. Plaintiff, FAEGRE & BENSON, LLP, MARK FISCHER, JUDY HEUMANN, NORMAN HEUMANN, BOULDER

More information

IN THE UNITED STATES DISTRICT COURT FOR NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

IN THE UNITED STATES DISTRICT COURT FOR NORTHERN DISTRICT OF TEXAS DALLAS DIVISION IN THE UNITED STATES DISTRICT COURT FOR NORTHERN DISTRICT OF TEXAS DALLAS DIVISION JPM NETWORKS, LLC, ) d/b/a KWIKBOOST ) ) Plaintiff, ) ) v. ) Civil Action No. ) 3:14-cv-1507 JCM FIRST VENTURE, LLC )

More information

COMPLAINT WITH JURY DEMAND. of police reports in bad faith. Plaintiff claims that Defendants acted willfully, wantonly and in

COMPLAINT WITH JURY DEMAND. of police reports in bad faith. Plaintiff claims that Defendants acted willfully, wantonly and in Weld County, Colorado, District Court, 901 9 th Avenue Greeley, CO 80631 970.351.7300 Plaintiff: vs. Defendants: JENNIFER BELL, individually and on behalf of all others similarly situated, BRADLEY PETROLEUM,

More information

Case 3:16-cv-02564 Document 1 Filed 05/12/16 Page 1 of 32 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Case 3:16-cv-02564 Document 1 Filed 05/12/16 Page 1 of 32 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Case :-cv-0 Document Filed 0// Page of Kimberly D. Barone Baden (CA SBN 0 Ann E. Rice Ervin Motley Rice LLP Bridgeside Boulevard Mount Pleasant, SC ( - (Phone ( -0 (Facsimile kbarone@motleyrice.com ariceervin@motleyrice.com

More information

Case3:14-cv-03680 Document1 Filed08/14/14 Page1 of 27

Case3:14-cv-03680 Document1 Filed08/14/14 Page1 of 27 Case:-cv-00 Document Filed0// Page of 0 THOMAS SIMS (SBN ) tsims@baronbudd.com RUSSELL BUDD rbudd@baronbudd.com BARON & BUDD, P. C. 0 Oak Lawn Ave, Suite 00 Dallas, Texas Telephone: () -0 Facsimile: ()

More information

Case 2:06-cv-15766-JF-SDP Document 69 Filed 02/25/2008 Page 1 of 15

Case 2:06-cv-15766-JF-SDP Document 69 Filed 02/25/2008 Page 1 of 15 Case 2:06-cv-15766-JF-SDP Document 69 Filed 02/25/2008 Page 1 of 15 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION FEDERAL TRADE COMMISSION, Plaintiff, v. MAZZONI

More information

The Effect of Product Safety Regulatory Compliance

The Effect of Product Safety Regulatory Compliance PRODUCT LIABILITY Product Liability Litigation The Effect of Product Safety Regulatory Compliance By Kenneth Ross Product liability litigation and product safety regulatory activities in the U.S. and elsewhere

More information

About the RECORD Clinical Trial Program

About the RECORD Clinical Trial Program About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

More information

SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO

SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO 1 0 1 MARC D. ADELMAN Attorney at Law State Bar No. Liberty Station Historic Decatur Road, Suite 00 San Diego, CA - (1) -0 Phone (1) -0 Fax Email: AdelmanMD@aol.com Attorney for Plaintiff SUPERIOR COURT

More information

Case 4:15-cv-00146-RH-CAS Document 1 Filed 03/17/15 Page 1 of 19 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF FLORIDA TALLAHASSEE DIVISION

Case 4:15-cv-00146-RH-CAS Document 1 Filed 03/17/15 Page 1 of 19 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF FLORIDA TALLAHASSEE DIVISION Case 4:15-cv-00146-RH-CAS Document 1 Filed 03/17/15 Page 1 of 19 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF FLORIDA TALLAHASSEE DIVISION CHRISTOPHER M. JENSEN, v. Plaintiff, LEON COUNTY, FLORIDA,

More information

Case: 4:15-cv-00194-CDP Doc. #: 23 Filed: 02/17/15 Page: 1 of 6 PageID #:

Case: 4:15-cv-00194-CDP Doc. #: 23 Filed: 02/17/15 Page: 1 of 6 PageID #: <pageid> Case: 4:15-cv-00194-CDP Doc. #: 23 Filed: 02/17/15 Page: 1 of 6 PageID #: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION KIEONNA LITTLEJOHN, et al., Plaintiffs, v.

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Case 2:15-cv-03432-DDP-AGR Document 1 Filed 05/07/15 Page 1 of 15 Page ID #:1 UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA

Case 2:15-cv-03432-DDP-AGR Document 1 Filed 05/07/15 Page 1 of 15 Page ID #:1 UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA Case :-cv-0-ddp-agr Document Filed 0/0/ Page of Page ID #: 0 Matthew T. Walsh, Esq. (Bar No. ) CARROLL, McNULTY & KULL LLC 00 North Riverside Plaza, Suite 00 Chicago, Illinois 00 Telephone: () 00-000 Facsimile:

More information